Novel Type 2 Diabetes Drugs Incur High Costs in Medicare Novel Type 2 Diabetes Drugs Incur High Costs in Medicare
In Medicare Part D, beneficiaries pay 3 to 8 times more out of pocket for SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors than for older glucose-lowering agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda Type 2 Diabetes Drugs and Their Use Are Top of EASD Agenda
The virtual 2020 meeting of the European Association for the Study of Diabetes will feature new data and insights on SGLT2 inhibitors and GLP-1 receptor agonists, technology, COVID-19, and much more.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 17, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys'DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 4, 2020 Category: Intensive Care Tags: Nephrology Commentary Source Type: news

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news

SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news

DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk SGLT2 Inhibitors With Metformin Do Not Up Fracture Risk
The combination of SGLT-2 inhibitors and metformin is not associated with an increase in fracture risk among patients with type 2 diabetes, according to a meta-analysis of 25 randomized, controlled trials.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 21, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Have a Breakout Year SGLT2 Inhibitors Have a Breakout Year
First indicated for type 2 diabetes, the benefits proven during the past year have thrust the drug class into the top tier of potential treatments for cardiac and renal disease.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 7, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported Unexpected Rosuvastatin-Canagliflozin Adverse Effect Reported
Canadian clinicians report the rare case of a 76-year-old woman who had a sharp spike in plasma levels of rosuvastatin within days of starting the SGLT2 inhibitor.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 5, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2 Inhibitors Commonly Used for Diabetes Linked to Higher Odds for a Serious Complication
TUESDAY, July 28, 2020 -- People taking a class of diabetes medications called SGLT2s have up to three times the risk for a serious complication called diabetic ketoacidosis (DKA) compared to people taking another drug, new research reveals. SGLT2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 28, 2020 Category: General Medicine Source Type: news

Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk Real-World Data Show SGLT2 Inhibitors for Diabetes Triple DKA Risk
Finding appears to be a class effect; drugs are also increasingly being used by cardiologists and nephrologists, so it's important they know about this rare but serious side effect.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 27, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Now'Belong to Cardiologists and Nephrologists'SGLT2 Inhibitors Now'Belong to Cardiologists and Nephrologists '
Physicians of different specialties are still getting used to the idea that SGLT2 inhibitors aren't just for diabetes anymore.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 17, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2is Beyond Diabetes: A Team Effort in CVD and Renal Disease SGLT2is Beyond Diabetes: A Team Effort in CVD and Renal Disease
As use of SGLT2 inhibitors expands, treatment of patients with diabetes, heart failure, and cardiovascular and renal disease requires close collaboration among specialists and primary care providers.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 16, 2020 Category: Cardiology Tags: Cardiology Commentary Source Type: news

VERTIS-CV Results'Disappoint,' Raise More Questions VERTIS-CV Results'Disappoint,' Raise More Questions
The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 2, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR Dapagliflozin's Renal Protection Extends to'Fast Decline' of eGFR
Treatment of patients with type 2 diabetes with the SGLT2 inhibitor led to a significant drop in the occurrence of'fast decline'of renal function in DECLARE-TIMI 58, the drug's main cardiovascular outcome trial.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 26, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

BEST: Bexagliflozin CV Outcomes Trial Meets Objectives BEST: Bexagliflozin CV Outcomes Trial Meets Objectives
Topline results of a cardiovascular outcomes trial of the investigational SGLT2 inhibitor for type 2 diabetes were presented at the ADA meeting and will be part of a new drug application to the US FDA.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 24, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT VERTIS-CV: Late-Comer Ertugliflozin Shows HF Benefit Only in CVOT
The findings are consistent with previous cardiovascular outcome trials of other SGLT2 inhibitors in type 2 diabetes, says an expert.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 18, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM GLP-1 Receptor Agonists vs SGLT2 Inhibitors for T2DM
How do these treatments for type 2 diabetes compare in terms of cardiovascular and renal outcomes and risk for adverse events?Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Those Most in Need Least Likely to Get Newer Diabetes Medications Those Most in Need Least Likely to Get Newer Diabetes Medications
Racial and socioeconomic disparities may be impeding access to newer diabetes medications, including DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors, among US patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF Dapagliflozin Benefits in HF Regardless of Diuretics: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease EU Green Light for Canagliflozin to Slow Diabetic Kidney Disease
The CHMP has recommended approval for the SGLT2 inhibitor canagliflozin (Invokana) be extended to include diabetic kidney disease.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 1, 2020 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news

Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF). (Source: Caring for the Ages)
Source: Caring for the Ages - June 1, 2020 Category: Health Management Authors: Christine Kilgore Source Type: news

Call for More Transparency in Gray Area of Post-Approval Drug Studies Call for More Transparency in Gray Area of Post-Approval Drug Studies
' Post-market safety studies are often inadequate, not completed, and poorly reported in the public arena,'say the authors of study examining SGLT2 inhibitors. But clinicians say this is not so black and white.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors May Prevent Diabetic Kidney Disease SGLT2 Inhibitors May Prevent Diabetic Kidney Disease
Patients with type 2 diabetes in real-world practice who received an SGLT2 inhibitor rather than a DPP-4 inhibitor were less likely to develop serious renal events, consistent with clinical trial findings.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 4, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors Linked to Reduced Risk for Serious Renal Events
FRIDAY, May 1, 2020 -- Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is associated with a reduced risk for serious renal events compared with dipeptidyl peptidase-4 inhibitors, according to a study published online April 29 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2020 Category: Pharmaceuticals Source Type: news

Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for...
In this free webinar, the speakers will review SGLT2 inhibitors and present emerging data on SGLT2 inhibitors and the impact on patients with type 2 DM and CKD.(PRWeb March 23, 2020)Read the full story at https://www.prweb.com/releases/sodium_glucose_transporter_2_inhibition_an_important_advancement_for_patients_with_type_2_diabetes_and_chronic_kidney_disease_upcoming_webinar_hosted_by_xtalks/prweb16996158.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news

FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections
A U.S. Food and Drug Administration (FDA) safety review has resulted in adding warnings to the labels of a specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors about the risks of too much acid in the blood and of serious urinary tract infections. Both conditions can result in hospitalization. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery FDA Says Stop SGLT2 Inhibitors for Diabetes Prior to Surgery
Label changes were approved by the FDA as surgery may put patients being treated with SGLT2 inhibitors at higher risk of ketoacidosis.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 18, 2020 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Renal Effects of SGLT2 Inhibitors: An Update Renal Effects of SGLT2 Inhibitors: An Update
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but what do we know about the renal effects of these drugs?Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 19, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

A New Perspective on Lowering CV Risk From Hypoglycemia A New Perspective on Lowering CV Risk From Hypoglycemia
A new study explores the relationship between hypoglycemia, cardiovascular outcomes, and treatment with an SGLT2 inhibitor. Might an SGLT2 inhibitor offer a cardio-protective effect?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

SGLT2 Inhibition: A New Avenue to Protect the Kidney SGLT2 Inhibition: A New Avenue to Protect the Kidney
Could SGLT2 inhibitors have a role in the management of patients with kidney disease? What are the benefits of these agents?Nephrology Dialysis Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 12, 2020 Category: Surgery Tags: Nephrology Journal Article Source Type: news

SGLT2 Inhibitors: Searching for Mechanisms SGLT2 Inhibitors: Searching for Mechanisms
Recent trials are exploring the role of SGLT2 inhibitors in cardiovascular disease, highlighting their clinical utility beyond diabetes. But their mechanism of cardiac effects remains unclear.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes
Sodium-glucose co-transporter-2 (SGLT2) inhibitors can cause ketoacidosis in patients with latent autoimmune diabetes (LADA), a report on three cases in the American Journal of Medicine confirms.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 22, 2020 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report - Nakamura M, Nakade J, Toyama T, Okajima M, Taniguchi T.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose. SGLT2 inhibitors have been reported to s... (Source: SafetyLit)
Source: SafetyLit - January 14, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Diabetes Drug Class May Hold Promise for Gout Prevention Diabetes Drug Class May Hold Promise for Gout Prevention
Adults with type 2 diabetes prescribed an SGLT2 inhibitor were less likely to develop gout than those prescribed a GLP-1 receptor agonist.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 13, 2020 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes
MONDAY, Jan. 13, 2020 -- Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2020 Category: Pharmaceuticals Source Type: news

Certain Diabetes Meds May Lower Gout Risk, Too
MONDAY, Jan. 13, 2020 -- Medications called SGLT2 inhibitors lower blood sugar in people with type 2 diabetes. And new research suggests these drugs may have an added benefit -- lowering the risk of gout. Compared with people taking another class... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 13, 2020 Category: General Medicine Source Type: news

Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

ADA Advises Wider Use of Newer Glucose-Lowering Drugs ADA Advises Wider Use of Newer Glucose-Lowering Drugs
In the 2020 Standards of Care, the American Diabetes Association advises consideration of SGLT2 inhibitors and GLP-1 receptor agonists in patients with high CVD or renal risk, regardless of A1c.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 20, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 inhibitors for diabetes are safe for older adults
According to a new study presented at the International Diabetes Federation (IDF) Congress 2019, SGLT2 inhibitors for the treatment of diabetes are safe and effective for older adults.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 20, 2019 Category: Endocrinology Source Type: news

SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults
Real-world study suggests that they work just as well in adults aged 65 and older, although the genital-urinary infection rate was high.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 19, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 10, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Highlights From ASN Kidney Week 2019 Highlights From ASN Kidney Week 2019
Highlights from ASN's Kidney Week 2019 include results from the CREDENCE trial showing benefit from the SGLT2 inhibitor canagliflozin for patients with established diabetic nephropathy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2019 Category: Consumer Health News Tags: Nephrology ReCAP Source Type: news

DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family
' What I don't want to see is slow uptake, once it gets the indication in nondiabetics,'said one physician. Think of SGLT2 inhibitors the same way as ACE inhibitors, beta blockers, and other HF drugs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 19, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Newer Diabetes Drugs Given to Those Who Need Them Least Newer Diabetes Drugs Given to Those Who Need Them Least
' The challenge we have [is that] SGLT2 inhibitors are currently underprescribed, and when they are prescribed,'they're not given to those patients likely to benefit most, says one expert.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 24, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news